Home

Aurobindo Pharma Ltd PE Ratio

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

PE

19.3

Last updated on: Jan 13, 2025

Key Highlights

  • The P/E Ratio of Aurobindo Pharma Ltd is 19.3 as of 13 Jan 13:17 PM .
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 years.
  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1167 as of 13 Jan 13:05 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Aurobindo Pharma Ltd

No data available

Company Fundamentals for Aurobindo Pharma Ltd

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

Share Price

₹ 1167.8

-32.30 (-2.69%)

stock direction

Last updated on: Jan 13, 2025

Market Price of Aurobindo Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
10 Jan 20251200.1
09 Jan 20251248.7
08 Jan 20251281.65
07 Jan 20251296.15
06 Jan 20251313.7
03 Jan 20251319.35
02 Jan 20251348.65
01 Jan 20251351.4
31 Dec 20241334.4
30 Dec 20241300.3

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

che

Weakness

2

che

Opportunity

0

che

Threats

1

che

BlinkX Score for Aurobindo Pharma Ltd

Asset Value vs Market Value of Aurobindo Pharma Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Aurobindo Pharma Ltd70318
Sun Pharmaceuticals Industries Ltd428533
Divis Laboratories Ltd153076
Cipla Ltd118723
Dr Reddys Laboratories Ltd112998

PE Ratio of Aurobindo Pharma Ltd Explained

``

70318

Market cap

3581

Earnings

19.3X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Aurobindo Pharma Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Aurobindo Pharma Ltd

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

Aurobindo Pharma Ltd News Hub

Aurobindo Pharma tumbles after US FDA issues warning letter to Telangana unit

In May 2024, the United States Food and Drug Administration (US FDA) had conducted an inspection at

Read more

2024-08-16 00:00:00

Eugia Pharma Specialities receives USFDA warning for Unit III

Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma S

Read more

2024-08-16 00:00:00

Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter

Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 2024 as agai

Read more

2024-08-12 00:00:00

Auro Pharma gets USFDA nod for atrophic vaginitis drug

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD)

Read more

2024-08-07 00:00:00

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Aurobindo Pharma Ltd

What is the current PE Ratio of Aurobindo Pharma Ltd?

The Current PE Ratio of Aurobindo Pharma Ltd is 19.28 as on 13 Jan 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 13 Jan 2025.

What was the PE Ratio of Aurobindo Pharma Ltd last year?

The PE Ratio of Aurobindo Pharma Ltd was 15.74 last year, now the PE ratio is 19.28, showing a year-on-year growth of 22.5%.

What does the PE Ratio of Aurobindo Pharma Ltd indicate about its stock?

The PE Ratio of Aurobindo Pharma Ltd is 19.28. This ratio indicates that investors are willing to pay 19.28 times the earnings per share for each share of Aurobindo Pharma Ltd.

What is the PE Ratio Growth of Aurobindo Pharma Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Aurobindo Pharma Ltd grew by 22.5% whereas, the EPS ratio grew by -10.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions